ct of LVFX on influenza virus-induced lung injury The findings MedChemExpress MEK162 reported herein confirm that LVFX exerts an anti-oxidative effect in an influenza virus infected mouse model. We used the dROMs test to evaluate the degree of oxidative stress because it has been reported that the level of hydroperoxide radicals, as measured by a dROMs test, was significantly increased in influenza virus infected mice. As shown in Fig 4A, at day 7 after infection with the influenza virus, the level of hydroperoxide radicals in the blood was significantly increased, but was significantly lowered by the administration of LVFX in a 
dose-dependent manner. In addition to ROS, NO production is also induced various virus infections, including influenza. Thus, we further examined the effect of LVFX on oxidative and nitrative stress in the lungs of influenza virus infected mice. In this experiment, changes in oxidative and nitrative stress were evaluated by the accumulation of 8-OHdG and NO2-Tyr, reactive metabolites of the peroxynitrite anion that is produced by the rapid reaction of NO and the superoxide anion, respectively. As shown in Fig 4B4D the levels of both 8-OHdG and NO2-Tyr in lung tissue on day 7 were markedly increased as the result of the influenza 9 / 16 Levofloxacin Protects against Influenza Virus-Induced Lung Injury virus infection ), while the LVFX treatment clearly decreased the levels of these oxidative and nitrative markers. Effect of LVFX on NOx and IFN- levels in BALF from influenza virusinfected mice Previous studies demonstrated that an overproduction of NO is induced by the elevation of IFN- levels in influenza virus infections. In addition, it was also reported that erythromycin can be of therapeutic value for influenza virus induced pneumonia, by inhibiting IFN- production and reducing the overproduction of NO in the lungs. To clarify the mechanism responsible for the inhibition of lung damage by LVFX, we examined the effect of LVFX on the level of both NOx and IFN- in BALF. Consistent with results reported in a previous study, the levels of both NOx and IFN- in BALF were markedly increased on day 7 after the influenza virus infection in our model. In such a circumstance, the administration of LVFX significantly suppressed the elevation of both NOx and IFN- levels. We also measured the decrease in the concentration of TNF- in BALF by the LVFX administration compared with the control. However, no differences were found between a LVFX dose of 25 mg/kg and a dose of 100 mg/kg. Discussion Recently reported experimental and clinical findings indicate that neutrophil-derived ROS and RNS play an important role in influenza virus-induced lung injuries and subsequent mortality. Thus, anti-oxidative PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/19711918 or anti-nitrative therapy represents a new strategy for combating influenza and related diseases. The findings reported herein show that LVFX has potent antioxidative and anti-nitrative properties that lessen the effects caused by a lung injury and consequently, improved the survival of mice that had been infected with the H1N1 influenza virus without changing the virus titer. It has been reported that FQs possess anti-oxidative and anti-nitrative properties that are independent of their anti-microbial activity. For example, Akamatsu et al. reported that ofloxacin, a racemic mixture of LVFX, showed PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/19710274 inhibitory activity against neutrophil-derived ROS . However, most of these studies were limited to in vitro assessments and only a few attempts to demonstra
